title: 1-Year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin.
abstract: 79 women who had been menopausal for less than 36 months and who had not received any form of treatment to prevent bone loss were randomly assigned to a 12-month regimen of calcium 500 mg/day or calcium 500 mg plus intranasal salmon calcitonin 50 IU/day for 5 days per week. After 12 months of treatment bone mineral density had decreased in the calcium-only group by a mean of 3.16 (SEM 0.6)% (p less than 0.01) but had increased in the calcium plus calcitonin group by 1.38 (0.8)% (NS). The difference in response between the two treatment groups was also highly significant (p less than 0.01), as was the difference between values for hydroxyprolinuria/creatininuria (p less than 0.01). Endogenous calcitonin levels rose significantly in the calcium group but remained unchanged in calcitonin-treated patients. Treatment by calcitonin and calcium was not followed by increased secretion of parathyroid hormone. The findings suggest that intranasal calcitonin can counteract early postmenopausal bone loss.
mesh_terms: D000281:Administration, Intranasal; D001842:Bone and Bones / Q000000981:diagnostic imaging; D002116:Calcitonin / Q000008:administration & dosage* / Q000627:therapeutic use; D002118:Calcium / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000652:urine; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D008903:Minerals / Q000032:analysis; D010024:Osteoporosis / Q000517:prevention & control*; D011877:Radionuclide Imaging; D011897:Random Allocation; D013607:Tablets / Q000009:adverse effects; D013997:Time Factors
chemical_list: D008903:Minerals; D013607:Tablets; C028815:salmon calcitonin; D002116:Calcitonin; D003404:Creatinine; D006909:Hydroxyproline; D002118:Calcium